MXPA04005207A - Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. - Google Patents
Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.Info
- Publication number
- MXPA04005207A MXPA04005207A MXPA04005207A MXPA04005207A MXPA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A MX PA04005207 A MXPA04005207 A MX PA04005207A
- Authority
- MX
- Mexico
- Prior art keywords
- manufacture
- antineoplastic agents
- farsenyl
- combination
- against cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33441101P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/037954 WO2003047697A2 (en) | 2001-11-30 | 2002-11-25 | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04005207A true MXPA04005207A (es) | 2004-08-19 |
Family
ID=23307076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04005207A MXPA04005207A (es) | 2001-11-30 | 2002-11-25 | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20030185831A1 (https=) |
| EP (1) | EP1448268A2 (https=) |
| JP (1) | JP2005511663A (https=) |
| CN (2) | CN1617755A (https=) |
| AU (1) | AU2002352941A1 (https=) |
| BR (1) | BR0214564A (https=) |
| CA (1) | CA2468839A1 (https=) |
| HU (1) | HUP0402401A2 (https=) |
| MX (1) | MXPA04005207A (https=) |
| NO (1) | NO20042730L (https=) |
| NZ (1) | NZ532562A (https=) |
| WO (1) | WO2003047697A2 (https=) |
| ZA (1) | ZA200403737B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533838A (ja) * | 2002-07-24 | 2005-11-10 | ノバルティス アクチエンゲゼルシャフト | 未分化甲状腺癌を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド |
| CA2439440A1 (en) * | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
| CA2544421A1 (en) * | 2003-11-06 | 2005-05-26 | Schering Corporation | Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| JP2007525507A (ja) * | 2004-02-26 | 2007-09-06 | ザ ペン ステイト リサーチ ファンデーション | オピオイド増殖因子レセプターを用いる、新生物の処置のための組み合わせ療法 |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| US20080255171A1 (en) * | 2005-10-07 | 2008-10-16 | Manley Paul W | Combination of Nilotinib with Farnesyl Transferase Inhibitors |
| WO2008051531A2 (en) * | 2006-10-25 | 2008-05-02 | Schering Corporation | Discontinuous methods of treating cancer |
| WO2008067144A2 (en) * | 2006-11-28 | 2008-06-05 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
| US20230390197A1 (en) * | 2020-10-27 | 2023-12-07 | Wisconsin Alumni Research Foundation | Modular dendron micelles for combination immunotherapy |
| AU2023376684A1 (en) | 2022-11-09 | 2025-06-19 | Merck Patent Gmbh | Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| DK1041985T3 (da) * | 1997-12-22 | 2006-06-19 | Schering Corp | Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme |
| US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| JP5491681B2 (ja) * | 2000-02-04 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 |
| US6838467B2 (en) * | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
| CA2397448A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| JP2003525239A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| EP1322334A2 (en) * | 2000-10-05 | 2003-07-02 | George Q. Daley | Methods of inducing cancer cell death and tumor regression |
-
2002
- 2002-11-25 CN CNA028239202A patent/CN1617755A/zh active Pending
- 2002-11-25 AU AU2002352941A patent/AU2002352941A1/en not_active Abandoned
- 2002-11-25 HU HU0402401A patent/HUP0402401A2/hu unknown
- 2002-11-25 MX MXPA04005207A patent/MXPA04005207A/es unknown
- 2002-11-25 CA CA002468839A patent/CA2468839A1/en not_active Abandoned
- 2002-11-25 US US10/303,259 patent/US20030185831A1/en not_active Abandoned
- 2002-11-25 EP EP02789901A patent/EP1448268A2/en not_active Withdrawn
- 2002-11-25 NZ NZ532562A patent/NZ532562A/en unknown
- 2002-11-25 CN CNA2007101860344A patent/CN101181269A/zh active Pending
- 2002-11-25 WO PCT/US2002/037954 patent/WO2003047697A2/en not_active Ceased
- 2002-11-25 JP JP2003548949A patent/JP2005511663A/ja not_active Withdrawn
- 2002-11-25 BR BR0214564-2A patent/BR0214564A/pt not_active IP Right Cessation
-
2004
- 2004-05-14 ZA ZA200403737A patent/ZA200403737B/en unknown
- 2004-06-29 NO NO20042730A patent/NO20042730L/no not_active Application Discontinuation
-
2006
- 2006-04-03 US US11/396,892 patent/US20060183765A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20042730L (no) | 2004-06-29 |
| WO2003047697A2 (en) | 2003-06-12 |
| AU2002352941A1 (en) | 2003-06-17 |
| ZA200403737B (en) | 2005-05-23 |
| WO2003047697A3 (en) | 2003-10-30 |
| US20060183765A1 (en) | 2006-08-17 |
| CA2468839A1 (en) | 2003-06-12 |
| JP2005511663A (ja) | 2005-04-28 |
| HUP0402401A2 (hu) | 2005-03-29 |
| EP1448268A2 (en) | 2004-08-25 |
| CN101181269A (zh) | 2008-05-21 |
| NZ532562A (en) | 2007-02-23 |
| US20030185831A1 (en) | 2003-10-02 |
| CN1617755A (zh) | 2005-05-18 |
| BR0214564A (pt) | 2004-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04005425A (es) | Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer. | |
| YU77000A (sh) | Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c | |
| WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
| MXPA05012421A (es) | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. | |
| GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
| WO2025049814A3 (en) | Ribonucleotide reductase (rnr) compositions and methods of use | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| ZA200703396B (en) | Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743 | |
| WO2002102306A3 (en) | Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy | |
| MY164077A (en) | Compositions and uses of et743 for treating cancer | |
| IL150953A0 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
| MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
| SI1689404T1 (sl) | Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka | |
| NZ504928A (en) | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases | |
| IL141550A0 (en) | Methods and compositions for the prevention or treatment of cancer | |
| GB0020504D0 (en) | Therapeutic method | |
| WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
| WO2001041747A3 (de) | Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs | |
| IL131478A0 (en) | Methods for treatment of scar tissue | |
| IL159770A0 (en) | Calcium salts with cytotoxic activity | |
| WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
| EP1374873B8 (en) | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy | |
| IL164356A (en) | Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer | |
| WO2006069217A3 (en) | Small molecule cyclin d1 ablative agents | |
| AU2450900A (en) | Therapeutic nucleoside compound |